Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

pegylated liposomal doxorubicin

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Generic mfg.

Drug class:

Topoisomerase II inhibitor

Related drugs:

‹

›

No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	bortezomib + pegylated liposomal doxorubicin Sensitive: A1 - Approval bortezomib + pegylated liposomal doxorubicin Sensitive : A1	bortezomib + pegylated liposomal doxorubicin Sensitive: A1 - Approval bortezomib + pegylated liposomal doxorubicin Sensitive : A1
No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	pegylated liposomal doxorubicin Sensitive: A1 - Approval pegylated liposomal doxorubicin Sensitive : A1	pegylated liposomal doxorubicin Sensitive: A1 - Approval pegylated liposomal doxorubicin Sensitive : A1
No biomarker	Breast Cancer	No biomarker	Breast Cancer	pegylated liposomal doxorubicin Sensitive: A1 - Approval pegylated liposomal doxorubicin Sensitive : A1	pegylated liposomal doxorubicin Sensitive: A1 - Approval pegylated liposomal doxorubicin Sensitive : A1
No biomarker	Kaposi Sarcoma	No biomarker	Kaposi Sarcoma	pegylated liposomal doxorubicin Sensitive: A1 - Approval pegylated liposomal doxorubicin Sensitive : A1	pegylated liposomal doxorubicin Sensitive: A1 - Approval pegylated liposomal doxorubicin Sensitive : A1
No biomarker	Fallopian Tube Cancer	No biomarker	Fallopian Tube Cancer	pegylated liposomal doxorubicin Sensitive: A2 - Guideline pegylated liposomal doxorubicin Sensitive : A2	pegylated liposomal doxorubicin Sensitive: A2 - Guideline pegylated liposomal doxorubicin Sensitive : A2
No biomarker	Peritoneal Cancer	No biomarker	Peritoneal Cancer	pegylated liposomal doxorubicin Sensitive: A2 - Guideline pegylated liposomal doxorubicin Sensitive : A2	pegylated liposomal doxorubicin Sensitive: A2 - Guideline pegylated liposomal doxorubicin Sensitive : A2
No biomarker	Peritoneal Cancer	No biomarker	Peritoneal Cancer	carboplatin + pegylated liposomal doxorubicin Sensitive: A2 - Guideline carboplatin + pegylated liposomal doxorubicin Sensitive : A2	carboplatin + pegylated liposomal doxorubicin Sensitive: A2 - Guideline carboplatin + pegylated liposomal doxorubicin Sensitive : A2
No biomarker	Fallopian Tube Cancer	No biomarker	Fallopian Tube Cancer	carboplatin + pegylated liposomal doxorubicin Sensitive: A2 - Guideline carboplatin + pegylated liposomal doxorubicin Sensitive : A2	carboplatin + pegylated liposomal doxorubicin Sensitive: A2 - Guideline carboplatin + pegylated liposomal doxorubicin Sensitive : A2
No biomarker	Sarcoma	No biomarker	Sarcoma	ifosfamide + pegylated liposomal doxorubicin Sensitive: A2 - Guideline ifosfamide + pegylated liposomal doxorubicin Sensitive : A2	ifosfamide + pegylated liposomal doxorubicin Sensitive: A2 - Guideline ifosfamide + pegylated liposomal doxorubicin Sensitive : A2
No biomarker	Sarcoma	No biomarker	Sarcoma	pegylated liposomal doxorubicin Sensitive: A2 - Guideline pegylated liposomal doxorubicin Sensitive : A2	pegylated liposomal doxorubicin Sensitive: A2 - Guideline pegylated liposomal doxorubicin Sensitive : A2
No biomarker	Endometrial Cancer	No biomarker	Endometrial Cancer	pegylated liposomal doxorubicin Sensitive: A2 - Guideline pegylated liposomal doxorubicin Sensitive : A2	pegylated liposomal doxorubicin Sensitive: A2 - Guideline pegylated liposomal doxorubicin Sensitive : A2
No biomarker	Bladder Cancer	No biomarker	Bladder Cancer	gemcitabine + ifosfamide + pegylated liposomal doxorubicin Sensitive: A2 - Guideline gemcitabine + ifosfamide + pegylated liposomal doxorubicin Sensitive : A2	gemcitabine + ifosfamide + pegylated liposomal doxorubicin Sensitive: A2 - Guideline gemcitabine + ifosfamide + pegylated liposomal doxorubicin Sensitive : A2